Array BioPharma and Genentech Expand Oncology Collaboration

Apr 07, 2005, 01:00 ET from Array BioPharma

    BOULDER, Colo., April 7 /PRNewswire-FirstCall/ -- Array BioPharma
 (Nasdaq:   ARRY) today announced an expansion of a collaboration agreement with
 Genentech, Inc. (NYSE:   DNA) to develop small molecule drugs against an
 additional protein target in the field of oncology.
     The original collaboration, which began in January 2004, was formed to
 advance two of Array's proprietary oncology programs into clinical
 development.  Under the expanded agreement, Array will receive additional
 research funding, as well as research and development milestone payments and
 product royalties based on the success of the new program.
     "We believe Genentech's expansion of our research collaboration further
 validates Array's leadership position in cancer research," said Robert E.
 Conway, Chief Executive Officer, Array BioPharma.  "This collaboration
 leverages Array's proprietary small molecule drug discovery expertise with
 Genentech's cancer expertise, with the goal of creating products to address
 one the world's largest unmet medical needs and market opportunities."
     Details of the Transaction
     Under the terms of this expanded agreement, Genentech and Array will
 collaborate on the discovery of clinical candidates directed against a cancer
 target, generated by Genentech.  Genentech will have the sole responsibility
 for clinical development and commercialization of the resulting products.
     About Array BioPharma
     Array BioPharma is a biopharmaceutical company focused on the discovery,
 development and commercialization of orally active drugs to address
 significant unmet medical needs.  Our proprietary drug development pipeline is
 primarily focused on the treatment of cancer and inflammatory disease and
 includes several small molecule drug candidates that are designed to regulate
 targets in therapeutically important biologic pathways.  In addition, leading
 pharmaceutical and biotechnology companies access our drug discovery
 technologies and expertise through collaborations to design, create, optimize
 and evaluate drug candidates across a broad range of therapeutic areas.  For
 more information on Array, please go to
     Array Forward-Looking Statement:
     This press release contains forward-looking statements within the meaning
 of the Private Securities Litigation Reform Act of 1995 that involve
 significant risks and uncertainties, including those discussed in our annual
 report filed on form 10-K for the year ended June 30, 2004, and in other
 reports filed by Array with the Securities and Exchange Commission.  Because
 these statements reflect our current expectations concerning future events,
 our actual results could differ materially from those anticipated in these
 forward-looking statements as a result of many factors.  These factors
 include, but are not limited to, our ability to achieve and maintain
 profitability, the extent to which the pharmaceutical and biotechnology
 industries are willing to in-license drug candidates for their product
 pipelines and to collaborate with and fund third parties for their drug
 discovery activities, our ability to out-license our proprietary candidates on
 favorable terms, our ability to continue to fund and successfully progress
 internal research efforts and to create effective, commercially viable drugs,
 risks associated with our dependence on our collaborators for the clinical
 development and commercialization of our out-licensed drug candidates, the
 ability of our collaborators and of Array to meet drug objectives, including
 clinical trials, tied to milestones and royalties, and our ability to attract
 and retain experienced scientists and management.  We are providing this
 information as of April 7, 2005.  We undertake no duty to update any forward-
 looking statements to reflect the occurrence of events or circumstances after
 the date of such statements or of anticipated or unanticipated events that
 alter any assumptions underlying such statements.

SOURCE Array BioPharma